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Abstract 
Background: In inflammatory bowel disease (IBD) number of thromboembolic events are 
increased due to hypercoagulupathy and platelet activation. Increases in mean platelet volume 
(MPV) can lead to platelet activation, this leads to thromboembolic events and can cause acute 
coronary syndromes. In IBD patients, QT-dispersion and P-wave dispersion are predictors of 
ventricular arrhythmias and atrial fibrilation; MPV is accepted as a risk factor for acute cor-
onary syndromes, we aimed at evaluating the correlations of these with the duration of 
disease, its localization and activity. 
Methods: The study group consisted of 69 IBD (Ulcerative colitis n: 54, Crohn’s Disease 
n:15) patients and the control group included 38 healthy individuals. Disease activity was 
evaluated both endoscopically and clinically. Patients with existing cardiac conditions, those 
using QT prolonging medications and having systemic diseases, anemia and electrolyte im-
balances were excluded from the study. QT-dispersion, P-wave dispersion and MPV values of 
both groups were compared with disease activity, its localization, duration of disease and the 
antibiotics used.  
Results: The P-wave dispersion values of the study group were significantly higher than those 
of the control group. Duration of the disease was not associated with QT-dispersion, and 
MPV levels. QT-dispersion, P-wave dispersion, MPV and platelet count levels were similar 
between the active and in mild ulcerative colitis patients. QT-dispersion levels were similar 
between IBD patients and the control group. No difference was observed between P-wave 
dispersion, QT-dispersion and MPV values; with regards to disease duration, disease activity, 
and localization in the study group (p>0.05). 
Conclusions: P-wave dispersion which is accepted as a risk factor for the development of 
atrial fibirilation was found to be high in our IBD patients. This demonstrates us that the risk 
of developing atrial fibrillation may be high in patients with IBD. No significant difference was 
found in the QT-dispersion, and in the MPV values when compared to the control group. 
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Introduction 
Crohn’s  disease  and  ulcerative  colitis  are  the 
main  entities  of  inflammatory  bowel  disease  (IBD). 
They are systemic diseases, which frequently involve 
other  organs  with  environmental,  genetic,  immune 
and microbial factors playing important roles in the 
etiology.  More than 40%  of patients with IBD have 
extraintestinal complications, involving almost every 
organ. Cardiac extraintestinal manifestations such as 
pericarditis,  myocarditis,  endocarditis,  cardiomyo-
pathy and complete heart block have been reported 
[1-4].  
Corrected  QT-interval  and  QT-dispersion  indi-
cate ventricular repolarization time and heterogenei-
ty. Increased corrected QT and/or QT-dispersion are 
known to be the cause of ventricular arrhythmia in 
various  systemic  diseases  and  lead  to  increase  in 
mortality  and  morbidity  [5-7].  Knorr  et  al.  demon-
strated  ciprofloxacin-induced  QT-interval  prolonga-
tion in patients diagnosed with IBD [8]. The reports 
regarding QT-interval and QT-dispersion in IBD with 
patients are inadequate.  
P-wave  dispersion  is  defined  as  the  difference 
between  the  maximum  and  the  minimum  P-wave 
durations  in  12-lead  surface  electrocardiograms. 
P-wave dispersion is considered to reflect the discon-
tinuous  and  inhomogeneous  propagation  of  sinus 
impulses, and the prolongation of atrial conduction 
time.  Increased  P-wave  dispersion  and  maximum 
P-wave  duration  predict  the  development  of  atrial 
fibrillation  in  patients  with  various  heart  diseases 
[9,10]. Sharma et al [11] reported that there was a sig-
nificant decrease in parasympathetic function in pa-
tients with IBD. Coruzzi et al [12] demonstrated the 
presence of autonomic dysfunction  in patients  with 
IBD, and that there was a decrease in parasympathetic 
cardiac regulation particularly in cases with ulcerative 
colitis.  But,  there  is  inadequate  data  about  P-wave 
dispersion.  In  IBD  patients  there  is  an  increase  in 
thromboembolic events due to increased hypercoag-
ulopathy  and  thrombocyte  activity.  This  is  an  im-
portant cause of mortality and morbidity. Incidence of 
the  risk  of  thromboembolism  ranges  between  1.2% 
and 39%. Increased mean platelet volume (MPV) may 
cause  platelet  activation,  which  in  turn  leads  to 
thromboembolic events and acute coronary syndrome 
[13,14]. 
Our aim in this study was to investigate the re-
lationship  of  QT-interval,  QT-dispersion;  which  are 
the predictors of ventricular arrhythmia; P-wave dis-
persion  the  predictor  of  atrial  fibrillation  and  MPV 
accepted as a risk factor for acute coronary syndrome 
with respect to disease duration, type and activity, in 
IBD patients with undetermined cardiac and ischemic 
diseases.  
Materials and Methods 
Patients and control group 
A total of 107 cases, between the ages of 18 and 
71 were included in the study, which was conducted 
between June 2008 and June 2009. Written informed 
consent was obtained from all participants following 
the decision of the Local Ethics Committee. The study 
group  consisted  of  69  IBD  patients  and  the  control 
group included 38 healthy individuals. The IBD pa-
tients were allocated into two groups for evaluation, 
the  ulcerative  colitis  group  (n=54)  and  the  Crohn’s 
disease group (n=15). Among the IBD patients, those 
with ulcerative colitis were subdivided as distal, left 
colon and pancolonic types, whereas in the Crohn’s 
disease group, patients with involvement of the colon 
were referred to as colonic while those with only ter-
minal ileum  involvement  were referred to as ileum 
[15].  There  were  no  patients  with  simultaneous  in-
volvement  of  terminal  ileum  and  colon.  Cardiovas-
cular risk factors of the patients and drugs used were 
recorded. Clinical activity of the disease was evalu-
ated  using  the  Truelove-Witts  criteria  in  ulcerative 
colitis patients [16], and the Crohn’s activity index in 
Crohn’s disease patients [17].  
Patients who developed severe anemia (Htc<30) 
from IBD were excluded from the study. Moreover, 
the patients with ischemia or structural heart disease, 
those who used QT-interval prolonging drugs, with 
systemic  diseases  like  hypertension  and  diabetes 
mellitus, pregnant women, alcoholics, obese (BMI>30) 
and  those  with  electrolyte  imbalance,  and  patients 
with any form of arrhythmia and conduction defect, 
were also excluded from the study. The control group 
consisted of healthy individuals who did not have a 
history of medication use due to any diseases, who 
did  not  have  any  systemic  diseases,  heart  diseases, 
cardiac  rhythm  problems  or  IBD  and  who  did  not 
have any abnormalities in their biochemical tests. 
QT and P wave dispersion measurement 
12-lead electrocardiograms (ECG) of all the pa-
tients were obtained at amplitude of 20mm/mV and a 
velocity of 50mm/s. The patients were subjected to 
manual ECG analyses by two cardiologists who were 
blinded  for  the  study.  QT-intervals  were  manually 
measured in all possible leads. The QT-interval was 
defined  as  the  interval  from  the  onset  of  the  QRS 
complex to the end of the T wave, which was defined Int. J. Med. Sci. 2011, 8 
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as its return to the T-P baseline. The measurements 
were carried out with a precision of 0.01 mm (0.4 ms). 
If  the  U  wave  was  present,  the  QT-interval  was 
measured to the nadir of the curve between the T and 
U waves.  
QT-intervals  were  corrected  by  the  Bazett’s 
Formula to compensate for its known dependence on 
heart rate: QTc =QT / √RR. Measurements on QT and 
RR intervals were carried out in 3 consecutive cardiac 
cycles in all leads, and average values were obtained 
[6]. QT-dispersion was determined as the difference 
between  the  maximal  and  minimal  corrected 
QT-interval in different leads. The beginning of the 
P-wave was defined as the point where the initial de-
flection of the P-wave crossed the isoelectric line, and 
the end of the P-wave was defined as the point where 
the final deflection of the P-wave crossed the isoelec-
tric  line.  The  difference  between  maximum  and 
minimum P-wave durations was defined as P-wave 
dispersion [6]. 
Echocardiography and blood tests 
Transthoracic  echocardiography  measurements 
(Vivid 3, General Electric Medical systems, USA) us-
ing a 3-MHz transducer were performed on patients 
in both the study and control groups. Left ventricular 
ejection fraction, left ventricular systolic and diastolic 
diameters, septal and posterior wall thickness, right 
ventricular and atrial diameters, the E/A ratio, and 
pulmonary arterial pressure measurements were ob-
tained  by  using  the  M-mode,  2-D,  Color  and 
Pulse-Continous  Doppler.  Blood  samples  were  col-
lected from the patients after a 12-hr overnight fast-
ing. All routine biochemical tests were carried out on 
an autoanalyser. For the analysis of MPV, blood sam-
ples with K3 EDTA were analyzed after one hour of 
venipuncture  by  the  Beckman  Coulter-LH  780  ana-
lyzer  (Beckman  Coulter,  U.S.A).  The  corrected  QT, 
QT-dispersion,  Pmax,  Pmin,  P-wave  dispersion  and 
MPV  values  of  both  groups  were  compared  with 
disease  duration,  activities,  localization,  types  and 
antibiotics administered.  
Statistical analyses 
The NCSS 2007&PASS 2008 Statistical Software 
(Utah,  USA)  program  was  used  for  statistical  anal-
yses.  Definitive  statistical  methods  (mean,  standard 
deviation,  frequency)  were  used  alongside  the 
One-way Anova test, and the Kruskal Wallis test for 
the comparison of data and quantitative data, respec-
tively. Comparison of parameters was performed us-
ing the Student t test, Mann Whitney U test and the 
Chi-square  test.  The  Pearson’s  correlation  test  was 
used to analyze the relationship between parameters. 
Results were evaluated at a 95% confidential interval 
and p<0.05 was considered as significant. 
Results  
Out of 107cases 54.2% were females and 45.8% 
were males. 21.7% of the  IBD patients had Crohn’s 
disease, whereas 78.3% had ulcerative colitis. Locali-
zation of the diseases was as follows: in the Crohn’s 
disease group 66.6% were in the ileum while 33.3% 
were colonic. On the other hand, of the ulcerative co-
litis patients 42.5% had pancolitis, 33.3% had left co-
lonic localization and 24% had distal colitis. Of all the 
IBD patients, 30.4% had severe disease, 33.3% were 
mild, while 36.2% were moderate. There was no dif-
ference between age, sex, cardiovascular risk factors, 
corrected QT, and QT-dispersion values between the 
IBD and the control group.  
Comparison  of  the  P-wave  variability  parame-
ters of both groups demonstrated that there was no 
significant  difference  between  the  Pmax  and  Pmin 
values  (p:  0.166,  p:  0.472  respectively);  The  P-wave 
dispersion  levels  of  IBD  patients  were  higher  than 
those of the control group (p: 0.027) (Table 1, Figure 
1). The MPV, hematocrit, platelet count and leucocyte 
count were similar between the two groups (p>0.05) 
(Table 1). There was no difference between the IBD 
types,  disease  duration,  localization,  activity  status, 
and  the  Pmax,  Pmin,  P-wave  dispersion, 
QT-dispersion, corrected QT and MPV levels (p>0.05) 
(Table 2). Moreover, the parameters did not differ in 
correlation with the localizations of ulcerative colitis 
and Crohn disease groups among themselves (Table 
3, 4). No relationship was found between the echo-
cardiographic  parameters  ejection  fraction,  left  ven-
tricular, left atrium, right atrium and right ventricular 
diameters, and the E/A ratio and pulmonary arterial 
pressure of the study and control groups (p>0.05). 
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Table 1: Group evaluation 
  Study group 
(n=69) 
Control group 
(n=38) 
p 
Mean±SD  Mean±SD 
 
Age  
LVEF (%) 
Pmax (ms) 
 
39.69±13.21 
64.10±5  
102.75±22.10 
 
41.59±13.12 
65.13±4 
97.89±13.59 
0.456 
0.158 
0.163 
Pmin (ms)  56.95±20.88  59.73±15.15  0.472 
Pd (ms)  45.50±16.98  38.15±14.86  0.027* 
QTd (ms)  76.68±31.99  79.92±28.31  0.603 
QTc (ms)  412.01±35.97  413.60±21.83  0.777 
WBC  7.65±2.32  7.47±1.93  0.235 
Hct  39.88±4.56  39.60±4.09  0.702 
MPV  8.51±1.34  8.56±0.83  0.584 
Plt   291.67±78.73  266.39±55.23  0.085 
The Student t test was used. * p<0.05; NS: None-significant 
LVEF=Left ventricular ejection fraction; Pmax=Maximum P-wave 
duration; Pmin=Minimum P-wave duration; Pd=P-wave disper-
sion; QTd=corrected QT dispersion; QTc=corrected QT interval; 
WBC=White blood cells; Hct=hematocrit; MPV=mean platelet 
volume; Plt=platelet count  
 
Table 2: Evaluation of parameters according to CD and 
UC disease types  
Study group  CD(n=15)  UC(n=54)  p 
Mean±SD  Mean±SD 
Pmax (ms)  111.00±31.40  100.46±18.48  0.232 
Pmin (ms)  61.67±31.26  55.65±17.13  0.484 
Pd (ms)  48.66±12.02  44.63±18.11  0.419 
QTd (ms)  76.13±35.32  76.83±31.37  0.941 
QTc (ms)  409.93±27.44  412.59±38.21  0.802 
MPV  8.28±1.38  8.58±1.34  0.454 
The Student t test was used. 
UC;Ulcerative colitis; CD;Crohn’s disease; Pmax=Maximum 
P-wave duration; Pmin=Minimum P-wave duration; Pd=P-wave 
dispersion; QTd=corrected QT dispersion; QTc=corrected QT in-
terval; MPV=mean platelet volume  
 
Table 3. Involvement related evaluations in UC patients  
UC  
Patients 
Pancolitis 
(n=23) 
Left Colon 
(n=18) 
Distal Colitis 
(n=13) 
p 
Mean±SD  Mean±SD  Mean±SD 
Pmax  97,60±21,20  107,22±15,64  96,15±15,29  0,161 
Pmin  56,08±17,58  57,78±14,77  51,92±19,95  0,644 
Pd  41,52±16,68  48,89±22,98  44,23±12,04  0,440 
QTd  80,48±30,23  78,17±27,33  68,53±38,86  0,544 
QTc  411,95±33,54  412,05±41,23  414,46±44,32  0,980 
MPV  8,19±0,94  8,72±1,50  9,05±1,59  0,157 
Oneway ANOVA test was used.  
UC;Ulcerative colitis; Pmax=Maximum P-wave duration; 
Pmin=Minimum P-wave duration; Pd=P-wave dispersion; 
QTd=corrected QT dispersion; QTc=corrected QT interval; 
MPV=mean platelet volume  
Table 4. Involvement related evaluations in CD patients  
CD patients  Ileum (n=10)  Colonic (n=5)  p 
Mean±SD (Me-
dian) 
Mean±SD (Me-
dian) 
Pmax  111,50±34,32 
(110) 
110,00±28,28 
(100) 
0,901 
Pmin  62,50±32,42 (50)  60,00±32,40 (40)  0,491 
Pd  49,00±13,09 (50)  48,00±10,95 (40)  0,851 
QTd  79,50±35,53 (70)  69,40±37,96 (56)  0,581 
QTc  409,00±25,64 
(410) 
411,80±33,89 
(396) 
0,806 
MPV  8,60±1,55 (8,17)  7,63±0,70 (7,60)  0,198 
Mann Whitney U test was used   
CD;Crohn’s disease; Pmax=Maximum P-wave duration; 
Pmin=Minimum P-wave duration; Pd=P-wave dispersion; 
QTd=corrected QT dispersion; QTc=corrected QT interval; 
MPV=mean platelet volume 
 
 
Discussion  
IBD  is  a  systemic  disease  associated  with  ex-
traintestinal manifestations, complications and other 
autoimmune  disorders  [18,19].  The  incidence  of  ex-
traintestinal  manifestations  ranges  between  6%-47% 
[20-23]. Although concomitance of IBDs with cardiac 
disorders is rare, sporadic cases of complication with 
pericardial  effusion,  pericarditis,  myocarditis,  endo-
carditis,  cardiomyopathy,  thromboembolic  events, 
conduction defects and drug use have been reported 
[3,24].  On  the  other  hand,  early  atherosclerosis  and 
thromboembolic events, and as a consequence cardi-
ovascular  mortality  are  known  to  increase  in  cases 
with IBD [25-28]. 
There is insufficient data concerning complica-
tions  such  as  electrocardiographic  abnormalities, 
sudden death, ventricular tachycardia, and atrial fi-
brillation in patients with IBD. Atrial fibrillation is a 
common type of arrhythmia; associated with compli-
cations such as thromboembolism, heart failure, and 
cardiomyopathy. Increase in P-wave dispersion is an 
indication of the heterogeneity of intra-atrial and in-
ter-atrial conduction and of anisotropic propagation 
of sinus impulses. P-wave duration and P-wave dis-
persion are the most important ECG markers used to 
evaluate the risk of atrial arrhythmias [9, 29].  
Various studies have demonstrated that P-wave 
dispersion has a predictive value for atrial fibrillation, 
in  cardiac  and  some  noncardiac  disorders.  In  the 
study by Dilaveris et al [30], the sensitivity and speci-
ficity for P-wave dispersion in paroxysmal idiopathic 
atrial fibrillation was found to be 83% and 85%, re-
spectively. In a study by Dogan et al [31], on Behçet’s 
disease and on rheumatoid arthritis by Guler et al [32] 
and Yavuzkır et al [33], increase in maximum P-wave Int. J. Med. Sci. 2011, 8 
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duration and P-wave dispersion were reported. In this 
study,  the  mean  values  of  the  patient  and  control 
group were, Pmax: 102.75±22.10 vs 97.89±13.59, Pmin: 
56.95±20.88  vs  59.73±15.15  and  P-wave  dispersion: 
45.50±16.98  vs  38.15±14.86,  respectively.  Results  of 
our study demonstrated that there was no increase in 
the maximum P-wave duration of patients with IBD 
when compared to the control group. However, in-
crease in P-wave dispersion was reported, suggesting 
that there was no association with the type, duration, 
activity and extent of the disease. In our study, in the 
IBH  group,  as  a  predictor  of  atrial  fibrillation  pre-
dicted P-wave dispersion value was found to be high 
as was the case in other studies. Some studies have 
been published concerning the controversial associa-
tion of autonomic dysfunction in patients with IBD. In 
their study, Sharma et al [11] and Coruzzi et al [12] 
reported that there was a significant decrease in par-
asympathetic function in patients with IBD.  
Autonomic  dysfunction  has  been  suggested  in 
various studies to be associated with local subclinical 
inflammation. Symptoms of cardiac autonomic dys-
function (like orthostatic hypotension, exercise intol-
erance, silent myocardial ischemia, etc.) were not re-
ported in our study group. There was no organic car-
diac  involvement  (myocarditis,  pericarditis,  cardio-
myopathy, etc.) in our patients, and there was no re-
ported  use  of  medication,  which  could  lead  to  ar-
rhythmia.  Notwithstanding,  we  are  of  the  opinion 
that decrease in parasympathetic activity; result of the 
effect of autonomic dysfunction  on  local  subclinical 
inflammation may play a role in the P-wave disper-
sion. These results demonstrate that there is a risk of 
atrial fibrillation in patients with IBD. Various studies 
have  demonstrated  that  increased  QT-interval  and 
QT-dispersion may increase the incidence of sudden 
death  and  ventricular  tachycardia  in  many  cardiac 
and noncardiac diseases (diabetes mellitus, systemic 
lupus  erythematosus,  sarcoidosis,  Behçet’s  disease, 
hypertension, hypertrophic cardiomyopathy), indica-
tion that it plays an important prognostic and clinical 
role [34-40]. In our study, corrected QT-interval and 
QT-dispersion were not found to be significant in the 
study  group  and  the  control  group  with  respect  to 
disease  duration,  type,  and  activity  (p=0.777  and 
p=0.603, respectively). Curione et al [41] found cor-
rected QT-interval and QT-dispersion to be  high  in 
the  IBD  group.  They  reported  the  necessity  to  fol-
low-up these QT changes in instances of electrolyte 
imbalances and in patients using cardiotoxic medica-
tions like infliximab and they stated that these should 
not  go  unreported.  By  taking  these  instances  into 
consideration, the patients in our study group were 
selected from among those patients who did not have 
a history of using cardiotoxic and QT –interval mod-
ifying  drugs  and  who  did  not  have  any  electrolyte 
imbalances. Knorr et al [8] demonstrated ciprofloxa-
cin-induced QT-interval prolongation in patients di-
agnosed with IBD. Patients in our study group didn’t 
use  ciprofloxacin  and  the  other  medications  which 
could induce QT-interval prolongation. No electrolyte 
imbalance, myocarditis, pericarditis and cardiomyo-
pathy  were  observed.  No  studies  have  been  docu-
mented on the association of autonomic dysfunction 
with corrected QT and QT-dispersion, in patients with 
IBD. Results of our study demonstrated that there is 
no heterogeneity of cardiac involvement and ventric-
ular repolarization in patients with IBD.  
Kapsoritakis  et  al  [13]  reported  an  increase  in 
platelet count and a decrease in the MPV in patients 
with  IBD. Platelet activation, increases in MPV and 
thromboembolic  events  have  been  reported  to  play 
important roles in the development and prognosis of 
acute coronary syndrome. Although the MPV values 
of our study group were lower than those in the con-
trol  group,  no  significant  relationship  was  demon-
strated with regards to the type, duration, activity and 
the  extend  of  the  disease.  There  are  also  studies 
showing that the decreases in MPV demonstrated an 
increase in IBD activity [42] and have not found this 
parameter  useful  in  differentiating  disease  activity 
[43] as has been the case in our study. Unlike acute 
coronary  syndrome  in  IBD  patients,  the  low  MPV 
levels in our study as well as in other studies, when 
compared  to  the  control  group,  suggests  that  the 
MPV, which is recognized as a risk factor for acute 
coronary syndrome in IBD patients may not be a risk 
factor on its own. 
Limitations  of  our  study  were  P-wave  and 
QT-interval  measurements  were  performed  using  a 
magnifying lens instead of by computer-assisted cal-
culations.  However,  thermal,  digital,  and  sig-
nal-averaging  ECG  systems  were  used  to  evaluate 
P-wave  dispersion,  which  was  measured  manually 
either  on  paper  or  on  a  high-resolution  computer 
screen. Our study had a small patient population; we 
suggest that extensive studies may be conducted with 
a large study population, holter recordings and au-
tonomic dysfunction tests. 
In conclusion, P-wave dispersion was not found 
to be associated with the duration, activity and extent 
of the disease, and was found to be significantly high 
compared  to  the  control  group.  This  demonstrates 
that the risk of developing atrial fibrillation may be 
high  in  patients  with  IBD.  However,  no  significant 
difference  was  found  in  the  corrected  QT  and 
QT-dispersion intervals, and in the MPV values when 
compared  to  the  control  group,  indicating  that  the Int. J. Med. Sci. 2011, 8 
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probability of ventricular arrhythmia or thromboem-
bolism and/or acute coronary syndrome may be low. 
It should be noted that simple, noninvasive, easy to 
use, easily accessible ECG can be used to determine 
the risk of atrial fibrillation in patients with IBD. 
Abbreviations 
IBD:  Inflammatory  bowel  disease,  MPV:  Mean 
platelet volume, ECG: Electrocardiograms. 
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